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Abstract 
Cryptoccocus neoformans infection is life threatening especially when associated with HIV disease. 
Unfortunately, in our environment, scant attention has been paid to screening for this fungal disease despite 
reports of relatively high co-infection rates with HIV in other countries facing similar HIV/AIDS burden. 
Among people living with HIV/AIDS, there is a significant population of pregnant women. In pregnancy itself, 
there is immunosuppression, thus combining with the immunosuppression seen in HIV disease. This study was 
therefore designed to determine the prevalence of cryptoccocus neoformans infection, among HIV seropositive 
pregnant women attending a prevention of mother to child transmission (PMTCT) of HIV treatment centre. Two 
hundred and eighty (280) women were recruited for the study. One hundred and sixty (160) of the subjects were 
HIV seropositive (test group) while 120 HIV seronegative pregnant women served as controls. The test group 
was sub-divided into three groups based on their CD4 counts: <200, 200-300 and >300 cells l. Blood was 
collected by venipuncture and HIV status was determined by current national serial algorithm using Determine 
and Stat Pak test kits. The test for Cryptoccocus neoformans was performed using latex cryptococcal antigen 
(CRAG) detection kits.CD4 counts was determined using the Partec cyflow analyzer.  A prevalence rate of 13.1% 
was observed among HIV seropositive subjects, while none (0%) of the control group tested positive. 
Cryptococcal antigenemia correlated with decreasing CD4 counts with most of the positive subjects having CD4 
counts below 200 cells/ l. It is recommended that targeted cryptococcal screening be made a part of baseline 
tests in HIV positive pregnant women with low CD4 + T cell counts. This will reduce preventable deaths and 
improve obstetric outcome in this vulnerable group.  
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Introduction 
Cryptococcosis is responsible for an estimated one million cases of meningitis per year, predominantly in HIV 
infected subjects (Alanio et al, 2011), and in sub-Saharan Africa, has been associated with 17% of all deaths 
among HIV-infected patients (French et al, 2002). There are two pathogenic variants: Cryptococcus neoformans 
var neoformans, which causes majority of the disease in persons with AIDS (Mitchell and Perfect, 1995), and 
Cryptococcus neoformans var gatti which rarely causes the disease in AIDS (Litvintseva et al, 2005).                                        
Cryptococcosis is acquired via inhalation of aerosolized particles from the environment (Saha et al, 2007). After 
inhalation, it is believed to lie dormant for many years. Reactivation, which occurs permanently among 
immunosuppressed individuals such as persons with HIV/AIDS, leads to infection, the common of which is 
meningitis (Roy and Chiller, 2011). AIDS associated cryptococcal meningitis (CM), caused by Cryptococcus 
neoformans, is a severe opportunistic infection with a high mortality, even in developed countries (Bicanic and 
Harrison, 2005). In Africa, CM is responsible for 13% to 42% of all deaths among HIV-infected people (Mwaba 
et al, 2001). CM is the AIDS-defining illness in 25% to 30% and 64% to 91% of cases in South-East Asia (Iyer 
and Banker, 2002) and sub-Saharan Africa (Schaars et al, 2006) respectively. C. neoformans is hypothesized to 
cause a sub clinical pulmonary infection which can evolve to a quiescent latent state with the potential for later 
reactivation in the context of acquired immunosuppression (Saha et al, 2007). Cryptococcal disease cannot be 
passed from person to person or from animal to person. A person with cryptococcal disease is not contagious 
(CDC, 2011).The fungus can affect a person’s lungs (Pneumonia) or the Central nervous system (Meningitis). C. 
neoformans is a common cause of meningitis in HIV/AIDS (Dismukes, 1998). According to the CDC, 
cryptococcal meningitis is a leading cause of death among persons living with HIV/AIDS in sub-Saharan Africa. 
With the advent of HIV/AIDS, the incidence of cryptococcosis is increasing and now represents a major threat of 
fungal infections in HIV patients. The HIV epidemic has facilitated an increase in the incidence of this infection, 
with HIV co-infection implicated in 80% of cases of cryptococcosis worldwide (Chayakulkeeree and Perfect, 
2006).  Furthermore, with the changes in the demography of Human Immunodeficiency Virus (HIV) infection, 
women and children are becoming the fastest growing groups of newly infected patients with Cryptococcus 
neoformans (Lipman et al, 2003). Among people living with HIV/AIDS, there is a significant population of 
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pregnant women. Pregnancy represents a vulnerable time for both mother and fetus, and is considered a period of 
relative immune suppression (Costa et al, 2009). In the pregnant state, the mother’s immunological status is 
downregulated in part to prevent fetal rejection due to paternally-derived histocompatibility antigens (Catanzara, 
1984). This immunosuppression is likely to be more severe in women infected with HIV; thus, they may be more 
susceptible to opportunistic infections like Cryptococcosis and post-surgical complications (Kwalombota, 2002).  
There is still no clear evidence that pregnancy is a predisposing factor for cryptococcosis, however, alteration of 
maternal T-cell activity, natural killer cells, polymorphonuclear leucocytes, macrophages and specific antibodies 
may play an important role in the development of this disease (Ely et al, 1988). Thus pregnancy could create a 
predisposition to opportunistic fungal infections due to relative immunosuppression (Ely et al, 1988).With 
increasing access to anti-retrovirals, opportunistic infections in HIV are declining. It has been reported though 
that only 37% of those in sub-Saharan Africa who are eligible for ART are receiving it (WHO/UNAIDS, 2010). 
Quite a number of the HIV infected do not present to hospital for medical care till they have progressed to AIDS. 
In individuals who have progressed to AIDS and/or have low CD4+ T cell counts, cryptococcosis is still a huge 
problem. 4.2% cryptococcus antigenemia was found among HIV positive individuals in a previous study in this 
environment (Chukwuanukwu et al, 2013). Thus, the aim of this study is to determine cryptococcal antigenemia 
among HIV seropositive pregnant women accessing ante-natal care in a Prevention of Mother to Child 
Transmission (PMTCT) of HIV treatment centre. 
 
SUBJECTS AND METHODS 
Subjects 
Two hundred and eighty (280) women were recruited for the study. One hundred and sixty (160) of the subjects 
were HIV seropositive (test group) while 120 HIV seronegative pregnant women served as controls. The 
participants were all pregnant women within the age of 18 and 40 years. The test group was divided into three 
categories based on their CD4 count; they are, those with CD4 count <200, a category with CD4 count between 
200-300 and another category with CD4 count >300 cells/ l
.
 One hundred and three (103) of the test group 
were on first line and second line antiretroviral drugs. Forty-four of these had been on antiretrovirals for six 
months or less. The participants were registered patients of HIV PMTCT clinic in Regina-Caeli Hospital Awka, 
Anambra State. 
Inclusion and Exclusion Criteria 
This study was delimited to the following:  Apparently healthy pregnant women that tested negative to HIV 
(control group) and pregnant women that tested positive to HIV. Non pregnant women were excluded. 
Ethical Consideration 
Ethical approval for this research was obtained from the Ethical committee of the Faculty of Health Sciences and 
Technology, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus. The consent of the 
subjects was also obtained. 
Methods 
 Blood was collected by venipuncture and HIV status was determined by current national serial algorithm using 
Determine and Stat Pak test kits. The test for Cryptoccocus neoformans was performed using latex cryptococcal 
antigen (CRAG) detection kits.CD4 counts was determined using the Partec cyflow analyzer.  
Determination of HIV status 
The tests were carried out according to the manufacturer’s instruction. 
Chembio HIV 1/2 STAT PAK
TM 
assay 
Principle of the test  
The chembio HIV 1/2 STAT PAK
TM
 assay employs a unique combination of a specific antibody- binding protein, 
which is conjugated to colloidal gold dye particles and HIV1/2 antigens which are bound to the membrane solid 
phase. The sample is applied through the sample well followed by the addition of running buffer. The buffer 
facilitates the lateral flow of the released products and promotes the binding of antibodies to the antigens. If 
present, the antibodies bind to the gold conjugate antibody-binding protein. In a reactive sample, the dye-
conjugate immune complex migrates through nitrocellulose membrane and is captured by the antigens 
immobilized in the test (T) area producing a pink/purple line. In the absence of HIV antibodies, there is no 
pink/purple line in the test (T) area. The sample migrates along the membrane and produces a pink/purple colour 
on the control (C) area containing immunoglobulin antigens. This control serves to demonstrate that specimens 
and reagents have been applied properly and have migrated through the device. 
 
DETERMINE 
TM 
FOR HIV -1/2 Detection  
The abbot Determine
TM
 HIV ½ is in vitro test kit, visually qualitative immune assay for the detection of 
antibodies to HIV – 1 and HIV – 2 in human serum, plasma or whole blood.  
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Principle of the test  
Determine HIV ½ is an immunochromatographic test for the qualitative detection of antibodies to HIV
HIV – 2. Sample migrates though the conjugate pad, it reconstitutes and mixes with the selenium colloid
conjugate. This mixture continues to migrate through the solid phase to the immobilized recombinant antigens 
and synthetic peptides in HIV – 1 or HIV 
antigen-selenium colloid and to the antigen at the patient window side. If antibodies to HIV
absent. The antigen selenium colloid flows past the patient window and no red line 
window site. To ensure assay validity, a procedural control bar is incorporated in the assay device.
 
CD4 T cell determination 
Principle of CD4 measurement 
Flow cytometry is a process by which cells or micropartilces in suspension
accordingly to the cell size, florescence, emission, and internal structure. In the cyflow counter, the fluorescence 
monoclonal antibody binds to the CD4 antigen  in a buffer suspension. The complex is passed through the flo
cuvette in a single stream flow. The complex is excited by the solid state at a wavelength of 532nm causing the 
emission of light by the complex which is captured by photomultiplier tube and transmitted into digital read out 
device as counts.  
Latex Cryptococcal Antigen Detection
The test for Cryptoccocus neoformans 
by IMMY.Procedure was according to the manufacturer’s instruction.
Principle: 
The Latex Cryptococcus Antigen Test is ba
particles will agglutinate with specimens containing Cryptococcal capsular polysaccharide antigen. Previously, 
the detection of this antigen in serum was hampered by the presence of rheum
specimen either pronage (REF DE0010) reduces nonspecific interference and enhances the detection of capsular 
polysaccharide antigen  
 
Results 
The findings from this study revealed positive cryptococcal antigenemia in the
positive. A prevalence rate of 13.1% was observed among HIV seropositive subjects (21 of the 160 test subjects 
tested positive), see fig 1, while none (
Fig 1: Cryptococcus neoformans status in HIV positive women attending PMTCT clinic
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Of the Twenty-one (21) subjects who were coinfected with Cryptococcus neoformans, eleven (11) had CD4 
counts below 200 cells l (52.4%), while nine (9) had CD4 counts between 200 -300 cells/ l, (42.8%). Only 
one subject was positive when the CD4 count was above 300 cells/ l (CD4 T cell count of 354 cells/ l).  None  
of the other subjects who had CD4 T cell count in the normal range tested positive for C. neoformans. The 
subject who had the highest CD4 count of 354 and was coinfected, had commenced anti-retroviral therapy seven 
(7) weeks prior to inclusion in the study. There was a significant decrease in the mean CD4 count levels of HIV 
sero-positive subjects co-infected with Cryptococcus neoformans when compared with HIV sero-positive 
subjects not infected,(P<0.05), thus, cryptococcal antigenemia correlated with decreasing CD4 counts. 
 
Fig 2: CD4 counts in the C.neoformans positive test subjects 
 
Discussion 
Cryptococcosis is responsible for an estimated one million cases of meningitis per year, predominantly in HIV 
infected subjects (Alanio et al, 2011). It has been associated with 17% of all deaths among HIV-infected patients 
in sub-Saharan Africa. With one million cases per year and 700,000 deaths, cryptococcosis is one of the most 
frequent invasive fungal infection worldwide (Park, 2009). 
 It has been reported that Infection with C.neorformans is thought to be common, however most 
immunocompetent individuals easily contain the infection (Saha et al, 2009). In the absence of effective CD4+ T 
cell responses, the organism can disseminate and eventually cross the blood –brain barrier to produce 
cryptococcal meningitis. Positive serum CRAG is relatively high in the study population. This may point in the 
direction of not just fresh infection with the fungi but also a reactivation of sub clinical pulmonary cyptococcal 
infection among these individuals.  Saha et al, 2007 hypothesized that quiescent latent cryptococcal infection 
may be reactivated in the context of immunosuppression. Studies have reported isolation of the causative agent 
in pigeons and other healthy birds (Iroakonulo,1999) and in the environment of the present study, bats which are 
common, are also a source with the causative organisms easily isolated in the rooftops of houses, churches and 
other public buildings (Mbata,2006). This provides ready sources of infection. In the control group, none of the 
subjects tested positive suggesting that the immunosuppression in a healthy pregnancy is not sufficient to cause 
either a reactivation or predisposition to new infection. The combination of the immunosuppression in pregnancy 
and HIV disease may likely increase the risk of contracting the opportunistic fungal infection. This is suggested 
by findings in a previous study in this environment which reported 4.2% cryptococcal antigenemia among HIV 
positive individuals (Chukwuanukwu et al, 2013). The result of 13.1% among pregnant women is definitely 
much higher. 
 It has been reported by numerous studies that most cryptococcal infections occur in patients with CD4 T cell 
counts less than 200 cells/ l ( Bicanic and Harrison, 2005,  Chayakulkeeree and Perfect,2006, Kaur et al, 2003, 
Perfect et al,2002, Yoo et al,2010). Majority of the infected subjects had CD4 T cell counts lower than 200 
cells/ l. However a significant number had CD4 T cell counts between 200 and 300. This may be due to 
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pregnancy and environmental factors. An individual had CD4 T cell count of 354 cells/ l and had already 
commenced ART. Literature reveals that while majority of those who present with cryptococcal meningitis are 
ART naïve, an increasing population are being diagnosed within the first 3 months after ART initiation ( Jarvais 
et al,2010, Lawn et al,2006).  
Cryptococcal antigen can be detected weeks before the onset of symptoms, and those who are asymptomatic but 
CRAG positive have a high risk of subsequent cryptococcal meningitis and mortality (Rajasingham, 2012). This 
may be part of the reason why most of the subjects were not down with the disease.  
  
Conclusion 
Urgent steps need to be taken to ensure early diagnosis, laboratory strengthening and clinical intervention in this 
infection, which is most likely under diagnosed, thus contributing to maternal mortality in this vulnerable group. 
It is recommended that targeted  cryptococcal screening be made a part of baseline tests in HIV positive 
individuals whose CD4 + T cell counts fall below 200 cells / l, more so in this group who are made more 
vulnerable due their pregnant state. This is recommended especially since there may be some confusion in 
symptoms due to already established HIV disease and other opportunistic infections/confounding factors. 
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